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Background
Nasal SIV vaccination can significantly protect from
AIDS progression.
Methods
We compared four mucosal routes of vaccination in
four groups of seven female Rhesus Macaques (RM)
each, immunized in the oral cavity (O), gastrointestinally
(GI), nasally (N) and vaginally (V) with mutated proviral
SIV, IL-2 and IL-15 DNAs and SIV rMVA. Vaccinated
and control animals were challenged vaginally with
repeated low-dose of SIVmac251.
Results
Only N vaccination induced a significant increase in
plasma SIV-IgG titers. Significantly higher systemic, rectal
and vaginal SIV-specific T-cell responses were detected in
the oral group during the immunization. The median
number of challenges required to become infected was sig-
nificantly higher in the GI group (32; 16 for O, 12 for V,
9 for N, 11 for controls). Repeated SIV exposure expanded
vaginal anti-SIV T-cells in some of the animals. Seven vac-
cinated RM (3 in the O, 3 in the N and 1 in the GI group)
suppressed the viremia after the initial infection peak and
maintained it undetectable over the course of the trial.
Immunized, infected animals had significantly lower levels
of systemic T-cell immune activation, better preservation
of CD4+ central memory and a4b7high+ CD4+ T-cells,
with consequent better protection from AIDS. However a
lower protection from AIDS progression was observed in
the GI group compared to the other vaccinated RM, with
a median survival of 24 weeks. A significantly higher loss
of CD4+ CM T-cells, detected early on in this group, cor-
rectly predicted its poor long-term outcome.
Conclusion
Protection from infection inT h eG Ig r o u pc o r r e l a t e d
with higher anti-SIV CD8+ T cells responses in vaginal
T-cells on the day of first challenge. More than 50% of
the O and N vaccinated RM were still disease-free 72
weeks after infection, and protection correlated with
levels of systemic anti-SIV IFN-g+/CD8+ T-cells on the
day of first challenge.
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